Literature DB >> 1474150

Performance of patients with early HIV-1 infection on the Stroop Task.

E M Martin1, L C Robertson, H E Edelstein, W J Jagust, D J Sorensen, D San Giovanni, V A Chirurgi.   

Abstract

HIV-seropositive and seronegative control subjects performed a standard paper-and-pencil version and an experimental reaction time version of the Stroop Color-Word Naming Task. Results indicated that both symptomatic and asymptomatic HIV-positive subjects showed an exaggerated Stroop effect compared to controls, but this increase was only apparent on the RT version of the task. Analysis of components of the effect indicated that HIV-positive subjects showed increased inhibition compared to controls but normal facilitation. These results suggest that HIV-related cognitive slowing has an attentional component, most likely involving controlled processes. In addition, these results emphasize the utility and sensitivity of RT measures in the study of early HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1474150     DOI: 10.1080/01688639208402867

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  12 in total

1.  Impact of the HIV Tat C30C31S dicysteine substitution on neuropsychological function in patients with clade C disease.

Authors:  Robert H Paul; John A Joska; Carol Woods; Soraya Seedat; Susan Engelbrecht; Jacqueline Hoare; Jodi Heaps; Victor Valcour; Beau Ances; Laurie M Baker; Lauren E Salminen; Dan J Stein
Journal:  J Neurovirol       Date:  2014-11-01       Impact factor: 2.643

2.  Are all drug addicts impulsive? Effects of antisociality and extent of multidrug use on cognitive and motor impulsivity.

Authors:  Jasmin Vassileva; Raul Gonzalez; Antoine Bechara; Eileen M Martin
Journal:  Addict Behav       Date:  2007-04-19       Impact factor: 3.913

3.  Iowa Gambling Task performance and emotional distress interact to predict risky sexual behavior in individuals with dual substance and HIV diagnoses.

Authors:  Margaret C Wardle; Raul Gonzalez; Antoine Bechara; Eileen M Martin-Thormeyer
Journal:  J Clin Exp Neuropsychol       Date:  2010-05-17       Impact factor: 2.475

4.  Disruption of emotion and conflict processing in HIV infection with and without alcoholism comorbidity.

Authors:  Tilman Schulte; Eva M Müller-Oehring; Edith V Sullivan; Adolf Pfefferbaum
Journal:  J Int Neuropsychol Soc       Date:  2011-05       Impact factor: 2.892

5.  Numeracy skills explain racial differences in HIV medication management.

Authors:  Drenna Waldrop-Valverde; Chandra Y Osborn; Allan Rodriguez; Russell L Rothman; Mahendra Kumar; Deborah L Jones
Journal:  AIDS Behav       Date:  2009-08-08

6.  Neurocognition, health-related reading literacy, and numeracy in medication management for HIV infection.

Authors:  Drenna Waldrop-Valverde; Deborah Lynne Jones; Felicia Gould; Mahendra Kumar; Raymond L Ownby
Journal:  AIDS Patient Care STDS       Date:  2010-08       Impact factor: 5.078

7.  Components of depression in HIV-1 infection: their differential relationship to neurocognitive performance.

Authors:  Steven A Castellon; David J Hardy; Charles H Hinkin; Paul Satz; Phillip K Stenquist; Wilfred G van Gorp; Hector F Myers; Larry Moore
Journal:  J Clin Exp Neuropsychol       Date:  2006-04       Impact factor: 2.475

8.  Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients.

Authors:  Allison J Applebaum; Michael W Otto; Mark A Richardson; Steven A Safren
Journal:  J Clin Exp Neuropsychol       Date:  2010-11-04       Impact factor: 2.475

9.  A family history of psychopathology modifies the decrement in cognitive control among patients with HIV/AIDS.

Authors:  Lance O Bauer
Journal:  Brain Cogn       Date:  2008-01-28       Impact factor: 2.310

10.  HIV-1 Infection, Injecting Drug Use, and Neuroendocrine Response to Psychological Stress.

Authors:  Raymond L Ownby; Drenna Waldrop-Valverde; Adarsh M Kumar; Deborah Jones; Benny Fernandez; Mahendra Kumar
Journal:  J HIV AIDS       Date:  2019-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.